The AI neurology market will grow from US$705.6m in 2025 to US$2.5bn by 2030, driven by rising neurological disorders.
The projected growth represents a compound annual growth rate of 28.9 per cent over the five-year period, as healthcare systems increasingly adopt AI tools for diagnosis and treatment of brain conditions.
AI technologies are transforming how clinicians detect and manage conditions including Alzheimer’s disease, Parkinson’s disease, stroke and epilepsy. The tools analyse brain scans, patient records and other medical data to identify patterns that human observers might miss.
Market research firm BCC Research reports that AI algorithms can now detect early signs of neurological disorders years before symptoms appear, using subtle changes in brain scans or speech patterns. This capability offers potential for earlier intervention in progressive conditions.
The expansion is being driven by several factors. The prevalence of neurological disorders is rising globally due to ageing populations and lifestyle factors, putting pressure on healthcare systems to find more efficient diagnostic and treatment methods.
Healthcare providers are also seeking tools for precision medicine, which tailors treatments to individual patients based on their specific characteristics and disease patterns. AI enables this by analysing complex datasets that would be impossible for humans to process manually.
Advances in neuroimaging technology have improved AI’s ability to detect abnormalities in brain scans. Deep learning algorithms can identify minute changes in brain structure or function that might indicate early-stage disease. Neuroimaging involves techniques that visualise the structure and function of the nervous system.
The technology is being applied across multiple areas. Applications include neuroimaging analysis, interpretation of electroencephalography (EEG) readings, clinical decision support systems, and drug discovery programmes. EEG measures electrical activity in the brain through electrodes placed on the scalp.
North America currently dominates the market, accounting for 47.2 per cent of the market in 2024. The region’s strong position reflects its advanced healthcare infrastructure, higher healthcare spending, and concentration of AI technology companies.
European and Asia-Pacific markets are also expanding rapidly as healthcare systems modernise and regulatory frameworks evolve to accommodate AI tools.
Brain-computer interface projects are emerging as a particularly innovative application. Companies like Neuralink are developing systems that could potentially restore movement or communication abilities in paralysed patients by creating direct connections between the brain and external devices.
However, the sector faces challenges. These include workforce shortages in rural areas and lower-income countries, high costs of implementing AI systems, and lack of standardised validation methods for AI-based neurology tools.
The absence of transparency in some AI algorithms also raises concerns among clinicians who need to understand how diagnostic recommendations are reached.
Market participants include established medical technology companies and specialised AI firms. Major players listed in the report include GE Healthcare, Siemens Healthineers, Philips, Medtronic and Canon, alongside AI-focused companies such as BrainQ Technologies, Brainomix and Viz.ai.
Investment is flowing into companies developing AI solutions for specific neurological conditions. Some firms focus on stroke detection and triage, while others specialise in epilepsy monitoring or neurodegenerative disease assessment.
The regulatory landscape is evolving to accommodate these technologies. Regulatory bodies are developing frameworks to evaluate AI tools while ensuring patient safety and efficacy standards are maintained.
As the technology matures, its integration into routine clinical practice is expected to accelerate, potentially improving outcomes for millions of patients with neurological conditions worldwide.
